CTOs on the Move

Longeveron

www.longeveron.com

 
Longeveron is a clinical stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. Their lead investigational product is Lomecel B™, which is derived from culture-expanded medicinal signaling cells ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lawrence Pharmaceuticals

Lawrence Pharmaceuticals is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mysite

Craft Health is a pharmaceutical drug delivery company that uses 3D printing technology to create personalized medicines and supplements for its customers.

WESKetch Architecture

WESKetch Architecture is a Millington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elixinol Global

The Elixinol Group operates (or intends to operate) in the industrial hemp and medicinal cannabis industries via Elixinol USA, Elixinol AUS and Hemp Foods Australia (HFA): • Elixinol USA is an established and profitable company which manufactures and distributes industrial hemp-based CBD dietary supplements and skincare products in the United States and in forty countries globally. • Elixinol AUS is a newly formed Australian company, which has not yet commenced operations and was formed to seek the required licences and permits to participate in the emerging Australian medicinal cannabis market. • HFA manufactures and distributes industrial hemp-derived food and skincare products mainly in Australia.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.